“Increasing Prevalence of Deadly Infectious Disease and Need For Highly Specific and Sensitive Technologies for Rapid Diagnosis to Drive Growth of the IDD Market
The global IDD market report is segmented by product, application, technology, end user, and region. The immunodiagnostics and polymerase chain reaction technology segments accounted for the lion’s share of the global IDD market by technology, owing to growing need for advanced technologies for rapid diagnosis of infectious diseases.
On the basis of application, the IDD market is categorized into the Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG), human papillomavirus (HPV), methicillin-resistant Staphylococcus aureus (MRSA), and others (Influenza, Ebola, Typhoid, Malaria, and Dengue, among others). Hospital-acquired MRSA infections, human papillomavirus, and AIDS are expected to be new revenue pockets in the applications market. The rising prevalence of these diseases globally is the major factor driving the growth of the aforementioned markets.
On the basis of product, the IDD market is segmented into instruments, consumables (reagents and assays), and software & services. Among products, consumables are estimated to be the fastest-growing market owing to its growing adoption in emerging infectious disease diagnostics worldwide.
On the basis of end user, the market is segmented into hospital laboratories, reference labs, physician’s office labs, academics, and others (blood banks, local public health laboratories, home health agencies, nursing homes, point of care, self-testing). Hospital laboratories are expected to be the fastest-growing market in the forecast period. Owing to the complexity and highly specialized nature of diagnostic tests for infectious diseases, hospital laboratories are expected to grow at the fastest rate in the forecast period, from 2014 to 2019.
From an insight perspective, this...